ClinicalTrials.gg

Program

IBI3016

A development code. Also written as “IBI3016 Dose 4”, “IBI3016 Dose 3” and “IBI3016 Dose 2”.

Its studies are mostly in Hypertension, led by Innovent Biologics.

Furthest: phase 2, since Jan 13, 20263 company-led studies, 3 open or runningNext primary completion: Jan 30, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Innovent Biologics33 open or runningphase 2since Jan 13, 2026Jan 13, 2026Jan 30, 2027phase 1 · NCT07838220

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 13, 2026First study: phase 2 study in HypertensionFirst studyNCT07352969 · 352 enrolled · China
  2. Apr 14, 2026Phase 1 study in HypertensionNCT07556796 · 30 enrolled · China
  3. Sep 13, 2026Phase 1 study in HypertensionNCT07838220 · 30 planned · Japan

Ahead

  1. Jan 30, 2027Primary completion: phase 1 study in HypertensionNCT07838220
  2. Oct 16, 2027Primary completion: phase 1 study in HypertensionNCT07556796
  3. Mar 27, 2029Primary completion: phase 2 study in HypertensionNCT07352969

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07838220Hypertension · Japan1RecruitingJan 30, 202730
NCT07556796Hypertension · China1Active, not recruitingOct 16, 202730
NCT07352969Hypertension · China2Active, not recruitingMar 27, 2029352

How it is read

Names in the registry

  • “IBI3016”, 2 entries
  • “IBI3016 Dose 4”, 1 entry
  • “IBI3016 Dose 3”, 1 entry
  • “IBI3016 Dose 2”, 1 entry
  • “IBI3016 Dose 1”, 1 entry

Codes read as this program: IBI3016.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.